Derzeitige Studien zur primären Hyperoxalurie und Studienzentren
A Phase 2, Multicenter, Open-Label, ExtensionStudy to Evaluate the Long-Term Administration of ALN-GO1 in patients with PrimaryHyperoxaluria Type 1ALN-GO1-002, RNAi Studie, subkutane Gabe von Lumasiran.
Zentrum: Universitätsklinikum Bonn, weitere Information unter info@hyperoxalurie-zentrum.de
An Open-Label Multi-Center Study in Patients with Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DCR-PHXC Solution for Injection (subcutaneous use). DCR-PHXC-101, RNAi Studie
Zentrum: Universitätsklinikum Bonn, weitere Information unter info@hyperoxalurie-zentrum.de
A phase III double-blind, randomised study to evaluate the long-term efficacy and safety of Oxabact® in patients with primary hyperoxaluria.
OC5-DB-02, Zentrum: Universitätsklinikum Bonn, weitere Information unter info@hyperoxalurie-zentrum.de
ALN-GO1-003 “ILLUMINATE-A: A Phase3 Randomized, Double-Blind, Placebo-Controlled Study with an Extended DosingPeriod to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults with Primary Hyperoxaluria Type 1”
Zentrum: Universitätsklinikum Bonn, weitere Information unter info@hyperoxalurie-zentrum.de
PilotStudy of ALLN-177(Oxalate decarboxylase) in Adult and Pediatric Subjects Aged12 Years or Older with Enteric or Primary Hyperoxaluria and Hyperoxalemia.
Zentrum: Charite,Berlin, Nierenstein/PH Sprechstunde, weitere Infos von anja.pfau@charite.de, UniversitätsklinikumBonn, weitere Information unter info@hyperoxalurie-zentrum.de
